Characterization of the Synergistic Inhibition of <i>I</i><sub>K(erg)</sub> and <i>I</i><sub>K(DR)</sub>
Ribociclib (RIB, LE011, Kisqali<sup>®</sup>), an orally administered inhibitor of cyclin-dependent kinase-4/6 (CDK-4/6) complex, is clinically effective for the treatment of several malignancies, including advanced breast cancer. However, information regarding the effects of RIB on membr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/21/8078 |